Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

al compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; inability or delay in establishing sales infrastructure to support potential commercialization; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates; and our ability to raise additional capital as needed. For further information regarding these and other risks r
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... (PRWEB) February 26, 2015 Innovation ... are emerging from unexpected parts of the world ... From agriculture to manufacturing to health care, ... and environmental realities and socio-political trends shake the ... the key ingredient for CEOs to survive the ...
(Date:2/26/2015)... Regis Technologies announced new potent ... drug substances. , Regis Technologies is proud to announce ... Compound Suite (PCS) for 2015. , Regis is a ... facility in Morton Grove, Illinois. The PCS addition will ... up to about one kilogram per batch. , ...
(Date:2/26/2015)... 26, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... at the Cowen 35 th Annual Health Care Conference ... Boston .  Lexicon management will provide an ... A webcast of the presentation will be available through Lexicon,s ... presentation will be available at www.lexpharma.com until April ...
(Date:2/26/2015)... , Feb. 26, 2015 Caris ... posters, at the 2015 Genitourinary Cancers Symposium in ... the clinical utility of tumor profiling. Both studies ... tumor profiling service, to identify biomarkers that shed ... cancer and small cell bladder cancer (SCBC). ...
Breaking Biology Technology:One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Regis Extends cGMP Services to Oncology Market 2Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5
... 30 Biotel Inc. (OTC Bulletin Board: BTEL) announced results ... earnings of $944,000, or $0.33 per diluted share, on revenues ... or $0.23 per diluted share on revenues of $11,495,000 in ... reported net earnings of $174,000 or $0.06 per diluted share, ...
... N.J., Sept. 30 DOR BioPharma, Inc. (OTC Bulletin Board: ... completed a corporate name change from DOR BioPharma, Inc. to ... the name change, the Company,s shares of common stock will ... of today. , "We are pleased to announce ...
... Valentine aka "DoctorLoopy" Wins Grand Prize with One-of-a-kind Video from Big Bend ... Voted for the Best Video Response to: "What Do America,s National Parks ... Park Foundation and Olympus announced today that ... TX, is the grand prize winner of the " Your Parks" ...
Cached Biology Technology:Biotel Announces Fourth Quarter and Year End Results 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4The National Park Foundation and Olympus Announce Winner of the First-Ever 'Your Parks' Video Challenge 2The National Park Foundation and Olympus Announce Winner of the First-Ever 'Your Parks' Video Challenge 3The National Park Foundation and Olympus Announce Winner of the First-Ever 'Your Parks' Video Challenge 4
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... Fungi play key roles in nature and are valued for ... in several foods and pharmaceuticals produced on a large-scale basis for ... . While A. niger is an integral player in ... be deployed in breaking down plant cell walls to free up ...
... has a photo of a cornfield and a big photovoltaic ... Washington University in St. Louis. "When I give talks I ... the audience votes overwhelmingly in favor of photosynthesis. " ... (below) is the point of departure for a provocative article ...
... (May 3, 2011) Cancer studies from Mercer University ... the American Association of Pharmaceutical Scientists, (AAPS) National Biotechnology ... -Wednesday, May 18 at the Hilton San Francisco Union ... for Cervical Cancer Cervical cancer is the ...
Cached Biology News:Same fungus, different strains 2Same fungus, different strains 3Turning plants into power houses 2Turning plants into power houses 3Turning plants into power houses 4Turning plants into power houses 5Turning plants into power houses 6AAPS national biotechnology conference to highlight breakthrough cancer treatments 2
Rad51B...
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
... monoclonal antibody reactive against the complex IV assembly ... in growing cultured cells. SURF1 is an important ... thought to participate in the folding of subunit ... Mutations of SURF1, particularly ones that result in ...
Phenytoin-BSA Isolated IgY DFc Drug...
Biology Products: